The General Meeting will be held as a virtual meeting via the online platform.
Key Business Items
The Notice of Meeting was released to the ASX today and contains important information regarding the items of business to be conducted at the General Meeting. Key resolutions include:
Resolution 1: Approval of the issue of 4,363,637 Placement Shares to Zheng Yang Biomedical Technology Co., Ltd (ZYBT) at A$0.55 per share, raising A$2.4 million to fund our pivotal Phase 3 clinical program for Elate Ocular®
Resolution 2: Approval of additional placement capacity of up to A$10,000,000 to support our registration-enabling clinical trials and provide financial flexibility
Independent Expert's Report
Shareholders should carefully consider the Independent Expert’s Report prepared by Hall Chadwick Corporate (NSW) Limited for the purposes of the shareholder approval required under section 611 (Item 7) of the Corporations Act. The Independent Expert has concluded that the transaction, the subject of Resolution 1, is fair and reasonable to non-associated shareholders of the Company.
Access Meeting Materials
The Notice of Meeting and Explanatory Statement are available on our website at www.cambium.bio/investors-and-media. The documents contain detailed information about each resolution, including the Board’s unanimous recommendation that shareholders vote in favour of all resolutions (with Sebastian Tseng abstaining from Resolution 1 due to his material personal interest).
Voting and Participation
Shareholders unable to attend in person are encouraged to submit their proxy votes by 11:00am (Sydney time) on Tuesday, 14 Shareholders unable to attend the virtual meeting are encouraged to submit their proxy votes by 11:00am (Sydney time) on Saturday, 14 March 2026. Proxy forms can be lodged online at https://au.investorcentre.mpms.mufg.com or via the methods outlined in the Notice of Meeting.
We also welcome your questions ahead of the meeting, which can be submitted to meetings-australia@acclime.com by 9 March 2026.
Looking Forward
This General Meeting comes at a pivotal time for Cambium Bio. With FDA Fast Track designation secured for Elate Ocular® and the Phase 3 clinical trial protocol approved, we are well-positioned to advance our lead product candidate through its final stages of clinical development. The proposed placement with ZYBT, our long-standing strategic partner since 2014, reflects their continued confidence in the clinical and commercial potential of Elate Ocular® for the treatment of dry eye disease. Your continued support is instrumental in advancing our clinical programs and creating long-term value for all stakeholders.
The Board looks forward to welcoming you to the Company’s General Meeting.
Yours faithfully,
Dr Edmund K. Waller Executive Chairman Cambium Bio Limited